Literature DB >> 25790882

Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up.

Yao-Jun Zhang1, Javaid Iqbal2, David van Klaveren3, Carlos M Campos4, David R Holmes5, Arie Pieter Kappetein4, Marie-Claude Morice6, Adrian P Banning7, Ever D Grech2, Christos V Bourantas4, Yoshinobu Onuma4, Hector M Garcia-Garcia4, Michael J Mack8, Antonio Colombo9, Friedrich W Mohr10, Ewout W Steyerberg3, Patrick W Serruys11.   

Abstract

BACKGROUND: Cigarette smoking is a well-known risk factor for development of coronary artery disease (CAD). However, some studies have suggested a "smoker's paradox," meaning neutral or favorable outcomes in smokers who have developed CAD, especially myocardial infarction (MI).
OBJECTIVES: The study aimed to examine the association of smoking status with clinical outcomes in the randomized controlled SYNTAX (SYNergy Between PCI With TAXUS and Cardiac Surgery) trial at 5-year follow-up.
METHODS: Detailed smoking history was collected at baseline, 6-month, 1-year, 3-year, and 5-year follow-up. The composite endpoints included death/MI/stroke (primary endpoint) plus major adverse cardiac and cerebrovascular events (MACCE) (combination of death/MI/stroke and target lesion revascularization) according to patient smoking status. The comparison of 5-year clinical outcomes between the groups according to smoking status was performed with Cox regression using smoking status at baseline or smoking as a time-dependent covariate.
RESULTS: A sizeable proportion (n = 322, 17.9%) of patients had changing smoking status during 5-year follow-up. One in 5 patients with complex CAD was smoking at baseline. However, 60% stopped after revascularization while others continued to smoke. Smokers had worse clinical outcomes due to a higher incidence of recurrent MI in both revascularization arms. Smoking was an independent predictor of the composite endpoint of death/MI/stroke (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.3 to 2.5; p = 0.001) and MACCE (HR: 1.4; 95% CI: 1.1 to 1.7; p = 0.02).
CONCLUSIONS: Smoking is associated with poor clinical outcomes after revascularization in patients with complex CAD. This places further emphasis on efforts at smoking cessation to improve revascularization benefits. (SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972).
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cessation; major adverse cardiac and cerebrovascular event(s); smoker’s paradox

Mesh:

Substances:

Year:  2015        PMID: 25790882     DOI: 10.1016/j.jacc.2015.01.014

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Preoperative cigarette smoking and short-term morbidity and mortality after cardiac surgery: a meta-analysis.

Authors:  Nicholas Gregory Ross Bayfield; Adrian Pannekoek; David Hao Tian
Journal:  Heart Asia       Date:  2018-10-24

2.  Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy.

Authors:  Javaid Iqbal; Patrick W Serruys
Journal:  Ann Transl Med       Date:  2017-03

3.  Effect of smoking on clinical outcomes in patients receiving rotational atherectomy in calcified coronary lesions: from the ROCK Registry, South Korea.

Authors:  Won Young Jang; Su Nam Lee; Sung-Ho Her; Donggyu Moon; Keon-Woong Moon; Ki-Dong Yoo; Kyusup Lee; Ik Jun Choi; Jae Hwan Lee; Jang Hoon Lee; Sang Rok Lee; Seung-Wan Lee; Kyeong Ho Yun; Hyun-Jong Lee
Journal:  Ann Saudi Med       Date:  2021-08-22       Impact factor: 1.526

4.  Smoking Does Not Affect Occlusion Rates and Morbidity-Mortality after Pipeline Embolization for Intracranial Aneurysms.

Authors:  A Rouchaud; W Brinjikji; H J Cloft; G Lanzino; T Becske; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-21       Impact factor: 3.825

5.  Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital.

Authors:  Sarah B Windle; Payam Dehghani; Nathalie Roy; Wayne Old; François R Grondin; Iqbal Bata; Ayman Iskander; Claude Lauzon; Nalin Srivastava; Adam Clarke; Daniel Cassavar; Danielle Dion; Herbert Haught; Shamir R Mehta; Jean-François Baril; Charles Lambert; Mina Madan; Beth L Abramson; Mark J Eisenberg
Journal:  CMAJ       Date:  2018-03-26       Impact factor: 8.262

6.  Smoker's Paradox in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Tanush Gupta; Dhaval Kolte; Sahil Khera; Prakash Harikrishnan; Marjan Mujib; Wilbert S Aronow; Diwakar Jain; Ali Ahmed; Howard A Cooper; William H Frishman; Deepak L Bhatt; Gregg C Fonarow; Julio A Panza
Journal:  J Am Heart Assoc       Date:  2016-04-22       Impact factor: 5.501

7.  Current trends in optimal medical therapy after PCI and its influence on clinical outcomes in China.

Authors:  Jian Zhang; Jing-Yan Hao; Rui Jing; Jing-Jing Liu; Cheng-Ye Di; Yu-Jie Lu; Peng Gao; Ya-Jie Wang; Rui-Fei Yang; Wen-Hua Lin
Journal:  BMC Cardiovasc Disord       Date:  2021-05-26       Impact factor: 2.298

8.  The bizzare phenomenon of smokers' paradox in the immediate outcome post acute myocardial infarction: an insight into the Malaysian National Cardiovascular Database-Acute Coronary Syndrome (NCVD-ACS) registry year 2006-2013.

Authors:  Padmaa Venkatason; Norsabihin Mohd Salleh; Yong Zubairi; Imran Hafidz; Wan Azman Wan Ahmad; Sim Kui Han; Ahmad Syadi Mahmood Zuhdi
Journal:  Springerplus       Date:  2016-04-26

9.  Serum VEGF Predicts Worse Clinical Outcome of Patients with Coronary Heart Disease After Percutaneous Coronary Intervention Therapy.

Authors:  Xia Han; Lili Liu; Jiamin Niu; Jun Yang; Zengtang Zhang; Zhiqiang Zhang
Journal:  Med Sci Monit       Date:  2015-10-26

10.  Sonolysis in Prevention of Brain Infarction During Cardiac Surgery (SONORESCUE): Randomized, Controlled Trial.

Authors:  David Školoudík; Eva Hurtíková; Radim Brát; Roman Herzig
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.